Epidemiological models for the spread of anti-malarial resistance
© Koella and Antia; licensee BioMed Central Ltd. 2003
Received: 9 December 2002
Accepted: 19 February 2003
Published: 19 February 2003
The spread of drug resistance is making malaria control increasingly difficult. Mathematical models for the transmission dynamics of drug sensitive and resistant strains can be a useful tool to help to understand the factors that influence the spread of drug resistance, and they can therefore help in the design of rational strategies for the control of drug resistance.
We present an epidemiological framework to investigate the spread of anti-malarial resistance. Several mathematical models, based on the familiar Macdonald-Ross model of malaria transmission, enable us to examine the processes and parameters that are critical in determining the spread of resistance.
In our simplest model, resistance does not spread if the fraction of infected individuals treated is less than a threshold value; if drug treatment exceeds this threshold, resistance will eventually become fixed in the population. The threshold value is determined only by the rates of infection and the infectious periods of resistant and sensitive parasites in untreated and treated hosts, whereas the intensity of transmission has no influence on the threshold value. In more complex models, where hosts can be infected by multiple parasite strains or where treatment varies spatially, resistance is generally not fixed, but rather some level of sensitivity is often maintained in the population.
The models developed in this paper are a first step in understanding the epidemiology of anti-malarial resistance and evaluating strategies to reduce the spread of resistance. However, specific recommendations for the management of resistance need to wait until we have more data on the critical parameters underlying the spread of resistance: drug use, spatial variability of treatment and parasite migration among areas, and perhaps most importantly, cost of resistance.
The treatment of malaria infections and the control of the spread of malaria are made increasingly difficult by drug resistant strains of the parasite. Resistance to chloroquine, an effective and safe anti-malarial that formed the first line of treatment, emerged more than 30 years ago , and since then malaria parasites have developed resistance against most of the widely used anti-malarials, including sulfadoxine-pyrimethamine [2, 3], mefloquine  and quinine . Indeed, it is now generally believed that the widespread use of a new drug will inevitably be followed by the appearance of resistance in the parasite population. There is, therefore, increasing emphasis in malaria control on rational management of drug use in an attempt, if not to prevent, then at least to delay the spread of resistance in the parasite population. One approach is to use combination therapy, where the simultaneous use of several drugs is hoped to delay the emergence of resistance [6, 7]. Another approach could be to use drugs in a mosaic fashion (temporally or spatially), so that resistance to individual drugs is counter-selected where or when the drug is not used, as is discussed for the management of antibiotic resistance . However, predicting the effect of different strategies for drug use on the spread of resistance to the drug is not straightforward because of the complex interactions that determine the transmission of the parasite between human and mosquito populations. Mathematical models have in the past provided a valuable framework for analysing the transmission dynamics of malaria [9, 10]. These models have been widely used to consider the effect of different strategies such as vector control  and the use of future vaccines on the transmission dynamics of malaria [12, 13].
In this paper, we extend these models to investigate the spread of drug resistance in malaria. We develop models of malaria transmission that allow us to examine the simplest case: the spread of resistance to a single drug, encoded at a single genetic locus. We modify standard epidemiological models of malaria transmission to incorporate drug sensitive and drug resistant parasite populations, and use this model to investigate the conditions under which drug resistance will spread in the population of hosts, as well as to predict the rate of spread of resistance. We then examine how superinfection or heterogeneity in treatment will modify the earlier results.
Our epidemiological models provide a counterweight to the recent models based on population genetic considerations [14–16]. One of the purposes of the paper is thus to discuss the similarities and differences in the predictions of the genetic and epidemiological models. But our main aims are to find which parameters would be necessary to predict the spread of resistance and to emphasize our lack of knowledge about any of these parameters.
Our models are based on previously published extensions of the classical Macdonald-Ross model, which take into account acquired immunity by humans and allow the duration of immunity to depend on exposure (i.e. that immunity is boosted by additional infections) [17, 18]. Though the assumptions about the development of immunity are undoubtedly overly simple, the model can predict several important epidemiological patterns, e.g. that the crude prevalence of malaria in a population may decrease at very high levels of transmission [19, 20]. Furthermore, variations of the model (where immunity is life-long or where the duration of immunity is constant, rather than being boosted by new infections) gave similar predictions, so that our results are robust with respect to details of the dynamics of immunity.
Susceptibles become infected at the inoculation rate h (which is derived below). Infected individuals recover at a rate r to become immune, and immunes loose their immunity and become susceptible again at a rate ρ. Deaths occur at a rate δ (i.e. the life-expectancy is 1/δ) and are not affected by disease status. Deaths are balanced by births into the susceptible class, so that the population size remains constant.
If the duration of immunity is ω years in the absence of new infections and immunity is boosted by re-exposure, reference  shows that the rate at which immunity is lost can be set to
Consider next the infection rate of mosquitoes. The mosquito population is split into three categories: a proportion v of infected mosquitoes that have not yet developed infectious sporozoites, a proportion w of infectious individuals with sporozoites in the salivary glands, and a proportion 1 - v - w of uninfecteds. Susceptible mosquitoes become infected by biting infected humans at a rate a; only a proportion b of the bites lead to infection. Thus the proportion of infected mosquitoes increases at a rate aby(1 - v - w). The newly infected mosquitoes become infectious to humans, if they survive the incubation period, τ, required for the development of the parasite. Assuming a mortality rate μ, a proportion e-μTsurvives this period. Thus, of the aby(1 - v - w) mosquitoes infected τ days earlier, aby(1 - v - w)e-μTmove from the latent to the infectious state. The proportions of latent and infectious mosquitoes decrease through mortality. The process of infection can thus be summarized as
Because the mosquito dynamics operate on a much faster time-scale than the human dynamics described by equation (1), the mosquito population can be considered to be at equilibrium with respect to changes in the human population. This allows its dynamics to be collapsed into the inoculation rate h:
where m denotes the number of mosquitoes per human.
As is customary for epidemiological models, transmission is summarized by the basic reproductive number, which gives the number of secondary cases following introduction of a single infected individual into a susceptible population.
As an indicator of the intensity of transmission, R o will tend to be increased by natural selection, and parasites with higher R o will invade populations of parasites with lower reproductive numbers.
Spread of resistance
The inoculation rates of sensitive and resistant parasites can be calculated as
where y S = y ST + y SU . The inoculation rate of the resistant parasites can be written as
We further assume that the differences in recovery rate are due to treatment and to a cost of resistance within the human host. Therefore
r SU <r R <r ST (9)
We can estimate the relative transmission of the sensitive and resistant parasites with their basic reproductive numbers. Letting equation (5) denote the basic reproductive number of the untreated, sensitive parasites and assuming that the average life-span of humans is considerably greater than the duration of infection (1/δ >> 1/r SU ), the basic reproductive number of the sensitive parasites (in the absence of resistant ones) becomes
where R o equals the basic reproductive number defined in equation (5), i.e. for sensitive parasites in the absence of treatment. The basic reproductive number of the sensitive infections declines linearly with increasing treatment. In the absence of resistance treatment can eradicate the disease, if it drives the basic reproductive number to less than unity, i.e. if the fraction of infections treated is larger than a critical value f e given by:
If we introduce resistant parasites, the outcome depends on the relative magnitude of the basic reproductive numbers of the sensitive and resistant infections. The latter is given by
where Γ = γ t r R /r SU describes the reduction of the intensity of transmission due to a switch from sensitivity to resistance and can therefore be defined as the total cost of resistance. The long-term outcome will depend on whether R R is larger than R S , which in turn depends on whether the proportion of individuals receiving treatment exceeds a threshold f c defined as
Thus, in this model, there is competitive exclusion between resistant and sensitive parasites. Whether sensitivity or resistance predominates in the population depends on three parameters: (i) the proportion of infected individuals that receive treatment, (ii) the effectiveness of treatment defined in terms of period of infection as ε = 1 - r SU /r ST , and (iii) the cost of resistance.
Superinfection of hosts
In the previous model we assumed that hosts cannot be superinfected by a second parasite, which would lead to mixture of sensitive and resistant parasites in the same patient. In this section we relax this assumption and allow superinfection of hosts, assuming that sensitive and resistant parasites develop independently within their host. We further assume that the treatment has a short half-life, so that the decision to treat superinfections is independent of any earlier treatment. In other words, a proportion f of all superinfections will be treated, while a proportion 1 - f will not be treated, irrespective of whether the first infection was treated or not. (We also analyzed a model where the treatment has a long-life and where the superinfecting parasite therefore receives the same treatment as the first infection. In this case, treated individuals cannot be superinfected with a sensitive parasite. The conclusions are the same as the ones reached with the equations given here). With these assumptions equations (6) can be modified to
where the subscript M denotes mixed infections. The inoculation rates of sensitive and resistant parasites are changed accordingly as
where y S = y ST + y SU and y M = y MT + y MU .
The possibility of coexistence of two parasite strains comes as no surprise. In many models of epidemiology, superinfection allows the coexistence of many strains, and in particular the coexistence of strains with considerable differences of transmission success .
Spatial variability in treatment rates
In this section, we relax a further assumption of the basic model: that drug treatment is applied uniformly to a population of hosts. In a natural situation, it is more likely that treatment levels will vary among host individuals and among host populations. We therefore ask, to what extent will gene flow via migration counteract the selective forces due to treatment in a local environment? To do so, we extend the model defined by equations (6) and (7) by assuming that the gene flow is due to migration of the mosquito vectors infected by sensitive or resistant parasites.
We will consider two cases. First, following work by Comins  we assume that there is a reservoir of untreated humans, where all parasites are sensitive. In the treated area, infection will be due partly to parasites surviving the treatment in this area and partly to parasites that have migrated from the untreated into the treated area. Second, we consider several human populations with differing treatment rates. Infected vectors migrate among neighbouring populations, so that they can migrate from the treated area to the untreated one.
Summary of results
Our models enable us to explore the consequences of changing the level of drug use on the frequency of resistant malaria parasites. In the simplest model, we find a threshold level of drug use, below which resistance cannot spread and above which resistance spreads and eventually becomes fixed. The threshold level is determined by the extent to which treatment of sensitive parasites reduces their duration of infection and by the cost of resistance, which is defined by the transmissibility of resistant parasites and by their duration of infection relative to untreated infections with sensitive parasites. This competitive exclusion between sensitive and resistant infections arises, because the parasite with the higher basic reproductive number R o drives the number of susceptible hosts below the threshold density that would be necessary to maintain the parasite with the lower basic reproductive number . This result is the counterpart to earlier studies on the spread of resistance in directly transmitted infections . It reflects that resistance is detrimental to the transmission of the parasite in untreated hosts, but beneficial in treated individuals, so that increasing drug use beyond a critical threshold tips the balance from 0% to 100% prevalence of resistance.
Allowing infection of hosts with both types of parasite gives similar results. The main differences are that, under some combinations of parameters, the resistant and sensitive parasites can coexist and that, for a low cost of resistance, resistant parasites can coexist with sensitive ones in the absence of treatment. This reflects the general conclusion that superinfection can maintain several parasite strains with different basic reproductive numbers . The parasite with low transmission success can infect hosts that are already infected by the more rapidly transmitted parasite. Therefore, evolution does not lead to competitive exclusion and does not maximize transmission, in contrast to models without superinfection.
Spatial variability in treatment rates can have a larger effect on the spread of resistance. High migration between areas with and without treatment can swamp the local effects of selection. Thus, when the cost of resistance is high, sensitive parasites can dominate in areas where every host receives treatment; when the cost of resistance is low, all parasites in areas where no treatment is available can become resistant. At intermediate costs of resistance and migration rates, coexistence of sensitive and resistant parasites is possible within each area. This coexistence arises as a balance between selection within the populations and migration between populations. Migrants (with the inappropriate type) can persist for some time before they are removed by selection (drug pressure or the cost of resistance) occurring within each population. Therefore, at some ratios of migration and selection, both types of parasites can coexist.
Thus, from the small number of models described here, it is clear that knowledge about several parameters is critical for our understanding of the spread of resistance: the drug use, the spatial variability of treatment and parasite migration among areas, and perhaps most importantly, the cost of resistance.
Unfortunately, data on any of these parameters are very limited, and almost completely restricted to chloroquine. Even data on the use of chloroquine, which may seem to be the easiest data to get, are poor. Though we may be able to estimate the total drug use in an area (e.g. 191 tons of chloroquine in Africa in 1988 ), though we may also obtain the consumption of the drug in an area (e.g. in endemic areas, large proportions of children have chloroquine residues in their blood at any given time ) and estimate the number of patients with clinical malaria receiving the drug, the more critical questions are: What proportion of infected people (as opposed to sick people) receive treatment, and is the dose of the drug sufficient to clear the parasites?
That resistance, at least against chloroquine, is costly in terms of transmission is suggested by the observation that resistance has dropped significantly in several areas when choloroquine was no longer used. In contrast, however, some data suggest that resistance is associated with a benefit, rather than a cost, in terms of transmission from humans to mosquitoes [26–28]. This is supported by in vitro studies of parasite development showing that resistant parasites grow more slowly than sensitive parasites, but develop their transmission stages earlier and at a higher rate . However, additional factors must balance and outweigh this apparent benefit of resistance, otherwise resistance would have spread before the wide-spread use of drugs. The genetic basis for the spread is given. Even before the use of a drug, resistance is present at low levels in many populations, in particular for quinine and proguanil . This probably applies for chloroquine as well, although the data are less convincing ). Possible factors leading to a cost of resistance might be related to the mortality of infected mosquitoes, since the parasite's transmission rate is more sensitive to mosquito mortality than to the effectiveness of transmission from humans to mosquitoes . Thus, the more effective transmission from humans to mosquitoes could be more than compensated by the higher mortality of heavily infected mosquitoes [32, 33]. Overall, there is some qualitative evidence for a cost of resistance, although quantitative measures of such a cost are absent.
Critique of the models
Obviously, like other mathematical (or non-mathematical) models, our equations are simple caricatures of the epidemiological processes being considered. The success of a model will depend on the inclusion of the relevant processes. There are several reasons for believing that the models we propose capture some aspect of reality. Compartment models of infectious diseases in general have had considerable success in epidemiology . In particular, compartment models similar to the ones used here can describe several epidemiological patterns of malaria , including, for example, the observation that increased transmission can decrease the malaria prevalence among adults of a population . Similar models are considered helpful in evaluating the sensitivity of malaria transmission to different control measures  and in predicting the effectiveness of vaccine programmes [13, 35]. Compartment models have also been used to examine the epidemiology of antimicrobial resistance in acute infections  as well as hospital acquired infections  and specific infections such as tuberculosis  and HIV . The current paper is a first attempt at applying them to anti-malarial resistance.
There are a number of specific problems with modelling the epidemiology of resistance to malaria, which we briefly discuss below. One set of problems concerns the epidemiological processes of malaria. In this category are problems associated with the lack of our understanding of the nature of immunity to malaria at the individual and epidemiological levels. Thus, the equations describing the development of immunity reflect the true process only crudely. However, simulations with two extreme alternative models (life-long immunity after the first infection or immunity without boosting, i.e. that is lost at a constant rate) suggest that our results are insensitive to the details of the immunological process. Furthermore, we have assumed that treatment does not affect the development of immunity. While we have no data on this issue for malaria, it is a reasonable assumption that is based on observations in other systems. The T-cell response to bacteria, for example, is programmed early in an infection (before the peak of the inflammatory response) and independent of the duration and severity of the bacterial infection. In other words, the infection starts the program, but has little influence on the further development of the immune response .
A second set of problems is associated with the genetics of malaria parasites. In this category falls the possibility that malaria is structured in distinct strains [40, 41]. This could slow the evolution of drug resistance if resistance is due to several genetic loci . This model and other models that take into account details of population genetics [14–16], as have population genetic models of the resistance of other parasites , show the importance and uses of population genetics. However, just as our equations neglect population genetics, these models have neglected the epidemiological processes underlying the evolutionary changes. From our models it appears that the neglect of epidemiology could qualitatively bias the results; the differences between competitive exclusion and coexistence, for example, can only be reached by explicitly contrasting different epidemiological assumptions and settings. Perhaps the best approach would be to merge epidemiological and genetic models. This approach has been taken several times in the recent literature with models taking into account individual infections [42–44], but it has some major disadvantages. Most importantly, because of the complexity of the models some important epidemiological features must be omitted. These models have not (or only in basic terms) taken account of acquired immunity, which is an important aspect of malaria epidemiology. If merging transmission and genetics is too complex, it remains to be seen whether focusing on the genetic side or on the epidemiological side will lead to better predictions. Certainly, where the genetics are simple (one locus), the epidemiological approach is more promising.
The approach offered here can provide insights into several aspects of the epidemiology of anti-malarial resistance. It remains unclear why chloroquine resistance has emerged much later in sub-Saharan Africa than in South-East Asia . This fact is often attributed to the high transmission in Africa, with the assumption that high transmission (and therefore strong acquired and innate immunity) leads to a slow spread of resistance . This assumption has indeed been found in some models of the spread of resistance, because intense transmission is associated with less inbreeding, which in turn can lead to slower spread of resistance under some conditions [15, 16]. However, this prediction is not universal, but depends on the details of the assumptions underlying transmission. Thus our model predicts either little or the opposite effect of transmission rate, while another recent model  shows that the within-host dynamics of malaria help to determine whether resistance is more likely to emerge in areas with high or with low transmission. But perhaps the explanation is much simpler: the use of chloroquine was fairly low until the mid-70s , so that resistance would be maintained at a low level due to the cost of resistance. As the chloroquine consumption increased to a peak of 191 tons in 1988 , it brought a rapid increase of resistance. Unfortunately, we do not have the quantitative data required to explore this possibility in more detail.
A further puzzle is that pyrimethamine resistance often spreads to areas not submitted to pyrimethamine pressure . One unlikely explanation is that resistance is associated with a benefit, rather than a cost. Another explanation could be that resistance spreads from areas with high drug consumption, provided the migration rate is sufficiently high and the cost of resistance is low.
Similarly, there appears to be a low, but non-negligible level of resistance in most geographical areas even before exposure to drugs . A possible explanation for this is a balance between mutation and selection , but it might also be explained by superinfection, which allows resistance to be maintained at low levels in areas in the absence of treatment, if resistance is not too costly.
Overall, an epidemiological approach could lead to valuable insights into the spread of resistance. What is needed is, on the one hand, investigation of the processes determining the spread and, on the other hand, more detailed knowledge of the critical parameters involved, e.g. cost of resistance. Only this will enable us to give advice about rational drug management that could slow the spread of resistance.
We thank several reviewers of previous versions of the manuscript for their helpful comments.
- Moore DV, Lanier JE: Observations on two Plasmodium falciparum infections with abnormal response to chloroquine. Am J Trop Med Hyg. 1961, 10: 5-9.PubMed
- Hakim SL, Roohi SWAS, Zurkurnai Y, Rain AN, Mansor SM, Palmer K, Navaratnam V, Mak JW: Plasmodium falciparum – increased proportion of severe resistance (RII and RIII) to chloroquine and high rate of resistance to sulfadoxine-pyrimethamine in peninsular Malaysia after 2 decades. Trans R Soc Trop Med Hyg. 1996, 90: 294-297.View Article
- Smithius FM, Monti F, Grundl M, Oo AZ, Kyaw TT, Phe O, White MJ: Plasmodium falciparum: sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar. Trans R Soc Trop Med Hyg. 1997, 91: 468-472.View Article
- Mockenhaupt F: Mefloquine resistance in Plasmodium falciparum. Parasitol Today. 1995, 11: 248-253. 10.1016/0169-4758(95)80201-0.View ArticlePubMed
- Benito A, Roche J, Molina R, Amela C, Alvar J: In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine in Equatorial Guinea. Am J Trop Med Hyg. 1995, 53: 526-531.PubMed
- White NJ: Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia. 1999, 41: 301-8.PubMed
- White N: Antimalarial drug resistance and combination chemotherapy. Phil Trans R Soc London B Biol Sci. 1999, 354: 739-49. 10.1098/rstb.1999.0426.View Article
- Bonhoeffer S, Lipsitch M, Levin BR: Evaluating treatment protocols to prevent antibiotic resistance. Proc Nat Acad Sci USA. 1997, 94: 12106-12111. 10.1073/pnas.94.22.12106.PubMed CentralView ArticlePubMed
- Macdonald G: The Epidemiology and Control of Malaria. London: Oxford University Press. 1957
- Dietz K, Molineaux L, Thomas A: A malaria model tested in the African savannah. Bull Wrld Hlth Assoc. 1974, 50: 347-357.
- Molineaux L, Gramiccia G: The Garki Project: Research on the Epidemiology and Control of Malaria in the Sudan Savanna of West Africa. Geneva: World Health Organization. 1980
- Halloran ME, Struchiner CJ: Modeling transmission dynamics of stage-specific malaria vaccines. Parasitol Today. 1992, 8: 77-85. 10.1016/0169-4758(92)90240-3.View ArticlePubMed
- Gupta S, Anderson RM: Predicting the effects of malaria vaccines on the population dynamics of infection and disease. In: Malaria Vaccine Development: A Multi-Immune Response Approach. Edited by: Hoffman SL. 1996, Washington DC: ASM Press, S24-276.
- Curtis CF, Otoo LN: A simple model of the build-up of resistance to mixtures of anti-malarial drugs. Trans R Soc Trop Med Hyg. 1986, 80: 889-892.View ArticlePubMed
- Dye C, Williams BG: Multigenic drug resistance among inbred malaria parasites. Proc R Soc London Ser B Biol Sci. 1997, 264: 61-67. 10.1098/rspb.1997.0009.View Article
- Hastings IM: A model for the origins and spread of drug resistant malaria. Parasitology. 1997, 115: 133-141. 10.1017/S0031182097001261.View ArticlePubMed
- Aron JL: Acquired immunity dependent upon exposure in an SIRS epidemic model. Math Biosc. 1988, 88: 37-47. 10.1016/0025-5564(88)90047-8.View Article
- Aron JL: Mathematical modelling of immunity to malaria. Math Biosc. 1988, 90: 385-396. 10.1016/0025-5564(88)90076-4.View Article
- Boyd MF: Epidemiology: factors related to the definitive host. In: Malariology. A Comprehensive Survey of All Aspects of This Group of Diseases from a Global Standpoint. Edited by: Boyd MF. 1949, Philadelphia: W.B. Saunders, 1: 608-697.
- Aron JL, May RM: The population dynamics of malaria. In: The Population Dynamics of Infectious Diseases: Theory and Applications. Edited by: Anderson RM. 1982, London: Chapman and Hall, 139-179.View Article
- Nowak MA, May RM: Superinfection and the evolution of parasite virulence. Proc R Soc London Ser B Biol Sci. 1994, 255: 81-89.View Article
- Comins HN: The development of insecticide resistance in the presence of migration. J theor Biol. 1977, 64: 177-197.View ArticlePubMed
- Bremermann HJ, Thieme HR: A competitive-exclusion principle for pathogen virulence. J math Biol. 1989, 27: 179-190.View ArticlePubMed
- Wernsdorfer WH: The development and spread of drug-resistant malaria. Parasitol Today. 1991, 7: 297-303. 10.1016/0169-4758(91)90262-M.View ArticlePubMed
- Kilombero Malaria Project: Household based malaria control in a highly endemic area of Africa (Tanzania): determinants of transmission and disease and indicators for monitoring. Memorias do Instituto Oswaldo Cruz. 1992, 87: 121-130.View Article
- Handunnetti SM, Gunewardena DM, Pathirana PPSL, Ekanayake K, Weerasinghe S, Mendis KN: Features of recrudescent chloroquine-resistant Plasmodium falciparum infections confer a survival advantage on parasites and have implications for disease control. Trans R Soc Trop Med Hyg. 1996, 90: 563-567.View ArticlePubMed
- Ichimori K, Curtis CF, Targett GAT: The effects of chloroquine on the infectivity of chloroquine-sensitive and -resistant populations of Plasmodium yoelii nigeriensis to mosquitoes. Parasitology. 1990, 100: 377-381.View ArticlePubMed
- Robert V, Molez J-F, Trape J-F: Short report: gametocytes, chloroquine pressure, and the relative parasite survival advantage of resistant strains of falciparum malaria in West Africa. Am J Trop Med Hyg. 1996, 55: 350-351.PubMed
- Koella JC: Linking evolutionary ecology with epidemiology. Rév Suisse Zool. 1994, 101: 865-874.View Article
- Peters W: Chemotherapy and Drug Resistance in Malaria. London: Academic Press. 1987
- Molineaux L: The epidemiology of drug resistance in malaria: an unfinished conceptual model. WHO informal consultation on the epidemiology of drug resistance of malaria parasites. 1986, Working paper 2.7.1:
- Anderson RA, Knols BJG, Koella JC: Plasmodium falciparum sporozoites increase feeding-associated mortality of their mosquito hosts Anopheles gambiae s.l. Parasitology. 2000, 120: 329-333. 10.1017/S0031182099005570.View ArticlePubMed
- Klein TA, Harrison BA, Grove JS, Dixon SV, André RG: Correlation of survival rates of Anopheles dirus A (Diptera: Culicidae) with different infection densities of Plasmodium cynomolgi. Bull Wrld Hlth Assoc. 1986, 64: 901-907.
- Anderson RM, May RM: Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press. 1991
- Koella JC: On the use of mathematical models of malaria transmission. Acta Trop. 1991, 49: 1-25. 10.1016/0001-706X(91)90026-G.View ArticlePubMed
- Lipsitch M, Bergstrom CT, Levin BR: The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Nat Acad Sci USA. 2000, 97: 1938-1943. 10.1073/pnas.97.4.1938.PubMed CentralView ArticlePubMed
- Blower SM, Small PM, Hopewell PC: Control strategies for tuberculosis epidemics: new models for old problems. Science. 1996, 273: 497-500.View ArticlePubMed
- Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO: Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med. 2001, 7: 1016-20. 10.1038/nm0901-1016.View ArticlePubMed
- Mercado R, Vijh S, Allen SE, Kerksiek K, Pilip IM, Pamer EG: Early programming of T cell populations responding to bacterial infection. J Immunol. 2000, 165: 6833-9.View ArticlePubMed
- Gupta S, Maiden MCJ, Feavers IM, Nee S, May RM, Anderson RM: The maintenance of strain structure in populations of recombining infectious agents. Nature Med. 1996, 2: 437-442.View ArticlePubMed
- Tibayrenc M, Ayala FJ: Towards a population genetic theory of micro-organisms: the clonal theory of parasitic protozoa. Parasitol Today. 1991, 7: 228-232. 10.1016/0169-4758(91)90234-F.View ArticlePubMed
- Cross AP, Singer B: Modelling the development of resistance of Plasmodium falciparum to anti-malarial drugs. Trans R Soc Trop Med Hyg. 1991, 85: 349-355.View ArticlePubMed
- Dye C: Population genetics of nonclonal, nonrandomly mating malaria parasites. Parasitol Today. 1991, 7: 236-240. 10.1016/0169-4758(91)90236-H.View ArticlePubMed
- Dye C: Models for investigating genetic exchange in protozoan populations. In: Modelling Vector-borne and Other Parasitic Diseases. Edited by: Perry BD, Hansen JW. 1994, Nairobi: ILRAD, 165-176.
- Hastings IM, Mackinnon MJ: The emergence of drug-resistant malaria. Parasitology. 1998, 117: 411-417. 10.1017/S0031182098003291.View ArticlePubMed
- Clyde DF: Malaria in Tanzania. Oxford: Oxford Univerity Press. 1967
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.